Hengrui Medicine's HER3 ADC approved for clinical trial

Jiangsu Hengrui Medicine announced that its subsidiary, Suzhou Sundia Biopharmaceuticals, received drug clinical trial approval from the National Medical Products Administration for SHR-A2009, an antibody-drug conjugate targeting HER3. The drug will proceed to an open-label, multi-center Phase IB/II clinical study to evaluate its safety, tolerability, and efficacy in patients with advanced solid tumors. To date, the cumulative R&D investment for SHR-A2009 projects totals approximately CNY 19,774万元. Global markets currently lack approved drugs of this type.

Concurrently, Jiangsu Hengrui Medicine released a progress update on its A-share repurchase program, initially disclosed on August 21, 2025. The company plans to repurchase shares worth between CNY 100,000万元 and CNY 200,000万元, with the repurchase period extending from August 20, 2025, to August 19, 2026. These repurchased shares are intended for employee stock ownership plans or equity incentives.

As of August 31, 2025, the company had not yet commenced the share repurchase. The maximum repurchase price is CNY 90.85 per share. Jiangsu Hengrui Medicine emphasized that the drug development process is lengthy and subject to uncertainties, urging investors to exercise caution.